Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04769362 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Beta-blocker Therapy After Acute Myocardial Infarction

Study acronym: SMART-DECISION
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 29, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 30, 2025 to Jan 31, 2026
    • Secondary endpoints revised (21)
    v9
  2. Secondary endpoints revised (21)v8
  3. Secondary endpoints: 19 to 21v7
  4. Study completion date: Mar 20, 2026 to Mar 31, 2026
    • Secondary endpoints revised (19)
    v6
  5. Secondary endpoints: 18 to 19v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Mar 20, 2026 to Oct 30, 2025
    • Secondary endpoints: details revised at 17 of 18 entries
    v4
  2. Primary endpoint revised
    • Eligibility criteria shortened, about 9 words
    • Secondary endpoints: 17 to 18
    • Collaborators revised (20)
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 20, 2021 to May 4, 2021
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI). Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without HF or left ventricular systolic dysfunction after AMI.
Trial Details
NCT Number NCT04769362
Lead Sponsor Samsung Medical Center
Collaborators: Kangbuk Samsung Hospital, Gyeongsang National University Hospital, Kyung Hee University Hospital, Keimyung University Dongsan Medical Center, Korea University Anam Hospital, Sejong General Hospital, Seoul National University Bundang Hospital, Samsung Changwon Hospital, Saint Vincent's Hospital, Korea, Presbyterian medical center, Wonkwang University Hospital, Wonju Severance Christian Hospital, Ewha Womans University Seoul Hospital, Inje University Ilsan Paik Hospital, Chonbuk National University Hospital, Chonnam National University Hospital, Jeju National University Hospital, Chosun University Hospital, Chungbuk National University Hospital, Chungnam National University Hospital
Conditions
(from sponsor)		 Myocardial Infarction
Related terms Myocardial Infarction
Enrollment 2,540 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov